THE KALLIKREIN-KININ PATHWAY IS DYSREGULATED IN HAE1
Uncontrolled plasma kallikrein leads to excessive bradykinin production2
Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; cHMWK=cleaved high molecular weight kininogen; FXII=factor XII; FXIIa=factor XIIa;
HMWK=high molecular weight kininogen; PKa=activated plasma kallikrein.
AN ESTABLISHED mAb TARGETING THE INHIBITION OF PLASMA KALLIKREIN TO REDUCE THE RELEASE OF BRADYKININ1
TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin, known to cause HAE attacks1
Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen;
mAb=monoclonal antibody; PKa=activated plasma kallikrein.
Just 1 subcutaneous injection, every 2 weeks1*
*The recommended starting dose for adults and adolescents is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
Review Dosing Information
See efficacy and safety across all 3 studies
Explore the results of the HELP study, the HELP open-label extension study, and the SPRING study.
Explore TAKHZYRO Data